Cargando…

Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells

Chimeric receptors comprising of the T-cell receptor-ζ cytoplasmic signalling chain fused to an extracellular ligand-binding domain of a single-chain antibody (scFv) have served as effective tools for redirecting cytotoxic T lymphocytes (CTL) against tumour cells. In this report, we constructed a ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gritzapis, A D, Mamalaki, A, Kretsovali, A, Papamatheakis, J, Belimezi, M, Perez, S A, Baxevanis, C N, Papamichail, M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747561/ https://www.ncbi.nlm.nih.gov/pubmed/12698199 http://dx.doi.org/10.1038/sj.bjc.6600888

Ejemplares similares

Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo
por: Gritzapis, A D, et al.
Publicado: (2005)

The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity
por: Dimitriadis, Alexios, et al.
Publicado: (2009)

Peptide HER2(776–788) represents a naturally processed broad MHC class II-restricted T cell epitope
por: Sotiriadou, R, et al.
Publicado: (2001)

Cytotoxic T-cell precursor frequencies to HER-2 (369 – 377) in patients with HER-2/neu-positive epithelial tumours
por: Sotiropoulou, P A, et al.
Publicado: (2003)

Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide
por: Voutsas, Ioannis F., et al.
Publicado: (2016)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas
por: Mineo, J-F, et al.
Publicado: (2004)

Frequencies of an Immunogenic HER-2/neu Epitope of CD8+ T Lymphocytes Predict Favorable Clinical Outcomes in Prostate Cancer
por: Goulielmaki, Maria, et al.
Publicado: (2023)

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
por: Schwab, C L, et al.
Publicado: (2014)

Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice
por: Coelho, M, et al.
Publicado: (2004)

Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice
por: Bruynzeel, A M E, et al.
Publicado: (2007)

Human responses against HER-2-positive cancer cells in human immune system-engrafted mice
por: De Giovanni, C, et al.
Publicado: (2012)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas
por: Berta, G N, et al.
Publicado: (2005)

Interleukin 1 beta synergises with interleukin 2 in the outgrowth of autologous tumour-reactive CD8+ effectors.
por: Baxevanis, C. N., et al.
Publicado: (1994)

Vaccination against Her-2/neu, with focus on peptide-based vaccines
por: Tobias, J., et al.
Publicado: (2022)

A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro
por: Abou El Hassan, M A I, et al.
Publicado: (2003)

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
por: Konecny, G E, et al.
Publicado: (2009)

In Vitro Activity and In Vivo Efficacy of Cefiderocol against Stenotrophomonas maltophilia
por: Nakamura, Rio, et al.
Publicado: (2021)

Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo
por: Bright, S A, et al.
Publicado: (2010)

Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy
por: Pisanu, M E, et al.
Publicado: (2014)

In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
por: Hager, Christopher L., et al.
Publicado: (2018)

T405, a New Penem, Exhibits In Vivo Efficacy against M. abscessus and Synergy with β-Lactams Imipenem and Cefditoren
por: Rimal, Binayak, et al.
Publicado: (2022)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
por: Shaw, Karen Joy, et al.
Publicado: (2018)

The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance
por: Toner, A P, et al.
Publicado: (2013)

3, 3′-diindolylmethane Enhances the Effectiveness of Herceptin against HER-2/Neu-Expressing Breast Cancer Cells
por: Ahmad, Aamir, et al.
Publicado: (2013)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
por: Evans, A H, et al.
Publicado: (2010)

In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway
por: Pils, D, et al.
Publicado: (2007)

SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii
por: Zurawski, Daniel V., et al.
Publicado: (2017)

Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death
por: Popelová, O, et al.
Publicado: (2009)

Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells
por: Bruynzeel, A M E, et al.
Publicado: (2007)

MicroRNAs for Fine-Tuning of Mouse Embryonic Stem Cell Fate Decision through Regulation of TGF-β Signaling
por: Hadjimichael, Christiana, et al.
Publicado: (2016)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Correlation of HER2/neu antibody response to clinical response in a Phase II trial of the ae37+gm-csf her2 peptide vaccine
por: Greene, Julia, et al.
Publicado: (2014)

Expression of Septin 2 and Her2/neu in Colorectal Cancer
por: Hanbuli, Hala M. El, et al.
Publicado: (2021)

MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity
por: Cebulla, J, et al.
Publicado: (2015)

In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer
por: Aird, R E, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_hsgjlv3kd2khvdecb4s4kn6jju